Literature DB >> 29727594

Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis.

Lucas D BonDurant1, Matthew J Potthoff1.   

Abstract

Fibroblast growth factor 21 (FGF21) is an endocrine hormone derived from the liver that exerts pleiotropic effects on the body to maintain overall metabolic homeostasis. During the past decade, there has been an enormous effort made to understand the physiological roles of FGF21 in regulating metabolism and to identify the mechanism for its potent pharmacological effects to reverse diabetes and obesity. Through both human and rodent studies, it is now evident that FGF21 levels are dynamically regulated by nutrient sensing, and consequently FGF21 functions as a critical regulator of nutrient homeostasis. In addition, recent studies using new genetic and molecular tools have provided critical insight into the actions of this endocrine factor. This review examines the numerous functions of FGF21 and highlights the therapeutic potential of FGF21-targeted pathways for treating metabolic disease.

Entities:  

Keywords:  FGF21; adipose; alcohol; macronutrient; thermogenesis; β-klotho

Mesh:

Substances:

Year:  2018        PMID: 29727594      PMCID: PMC6964258          DOI: 10.1146/annurev-nutr-071816-064800

Source DB:  PubMed          Journal:  Annu Rev Nutr        ISSN: 0199-9885            Impact factor:   11.848


  150 in total

1.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.

Authors:  Jody Dushay; Patricia C Chui; Gosala S Gopalakrishnan; Marta Varela-Rey; Meghan Crawley; Ffolliott M Fisher; Michael K Badman; Maria L Martinez-Chantar; Eleftheria Maratos-Flier
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

Review 2.  Obesity: the protein leverage hypothesis.

Authors:  S J Simpson; D Raubenheimer
Journal:  Obes Rev       Date:  2005-05       Impact factor: 9.213

3.  Novel locus including FGF21 is associated with dietary macronutrient intake.

Authors:  Audrey Y Chu; Tsegaselassie Workalemahu; Nina P Paynter; Lynda M Rose; Franco Giulianini; Toshiko Tanaka; Julius S Ngwa; Qibin Qi; Gary C Curhan; Eric B Rimm; David J Hunter; Louis R Pasquale; Paul M Ridker; Frank B Hu; Daniel I Chasman; Lu Qi
Journal:  Hum Mol Genet       Date:  2013-01-30       Impact factor: 6.150

4.  Long-Term Cold Adaptation Does Not Require FGF21 or UCP1.

Authors:  Susanne Keipert; Maria Kutschke; Mario Ost; Thomas Schwarzmayr; Evert M van Schothorst; Daniel Lamp; Laura Brachthäuser; Isabel Hamp; Sithandiwe E Mazibuko; Sonja Hartwig; Stefan Lehr; Elisabeth Graf; Oliver Plettenburg; Frauke Neff; Matthias H Tschöp; Martin Jastroch
Journal:  Cell Metab       Date:  2017-08-01       Impact factor: 27.287

5.  Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels.

Authors:  Daniel Cuevas-Ramos; Paloma Almeda-Valdes; Francisco J Gómez-Pérez; Clara Elena Meza-Arana; Ivette Cruz-Bautista; Olimpia Arellano-Campos; Mariana Navarrete-López; Carlos A Aguilar-Salinas
Journal:  Eur J Endocrinol       Date:  2010-06-21       Impact factor: 6.664

6.  Defining the Nutritional and Metabolic Context of FGF21 Using the Geometric Framework.

Authors:  Samantha M Solon-Biet; Victoria C Cogger; Tamara Pulpitel; Marika Heblinski; Devin Wahl; Aisling C McMahon; Alessandra Warren; Jessica Durrant-Whyte; Kirsty A Walters; James R Krycer; Fleur Ponton; Rahul Gokarn; Jibran A Wali; Kari Ruohonen; Arthur D Conigrave; David E James; David Raubenheimer; Christopher D Morrison; David G Le Couteur; Stephen J Simpson
Journal:  Cell Metab       Date:  2016-09-29       Impact factor: 27.287

7.  Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus.

Authors:  W-W Chen; L Li; G-Y Yang; K Li; X-Y Qi; W Zhu; Y Tang; H Liu; G Boden
Journal:  Exp Clin Endocrinol Diabetes       Date:  2007-10-09       Impact factor: 2.949

8.  Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor?

Authors:  Takashi Uebanso; Yutaka Taketani; Hironori Yamamoto; Kikuko Amo; Hirokazu Ominami; Hidekazu Arai; Yuichiro Takei; Masashi Masuda; Ayako Tanimura; Nagakatsu Harada; Hisami Yamanaka-Okumura; Eiji Takeda
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

9.  Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.

Authors:  Alberto O Chavez; Marjorie Molina-Carrion; Muhammad A Abdul-Ghani; Franco Folli; Ralph A Defronzo; Devjit Tripathy
Journal:  Diabetes Care       Date:  2009-06-01       Impact factor: 19.112

10.  FGF21 promotes metabolic homeostasis via white adipose and leptin in mice.

Authors:  Murielle M Véniant; Clarence Hale; Joan Helmering; Michelle M Chen; Shanaka Stanislaus; Jim Busby; Steven Vonderfecht; Jing Xu; David J Lloyd
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

View more
  58 in total

1.  Fibroblast Growth Factor-21 Controls Dietary Protein Intake in Male Mice.

Authors:  Karlton R Larson; Aki T-B Chaffin; Michael L Goodson; Yanbin Fang; Karen K Ryan
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

2.  Sex-specific brain erythropoietin regulation of mouse metabolism and hypothalamic inflammation.

Authors:  Soumyadeep Dey; Zhenzhong Cui; Oksana Gavrilova; Xiaojie Zhang; Max Gassmann; Constance T Noguchi
Journal:  JCI Insight       Date:  2020-03-12

3.  FGF21 Signals to Glutamatergic Neurons in the Ventromedial Hypothalamus to Suppress Carbohydrate Intake.

Authors:  Sharon O Jensen-Cody; Kyle H Flippo; Kristin E Claflin; Yavuz Yavuz; Sarah A Sapouckey; Grant C Walters; Yuriy M Usachev; Deniz Atasoy; Matthew P Gillum; Matthew J Potthoff
Journal:  Cell Metab       Date:  2020-07-07       Impact factor: 27.287

Review 4.  A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21.

Authors:  Steven A Kliewer; David J Mangelsdorf
Journal:  Cell Metab       Date:  2019-02-05       Impact factor: 27.287

Review 5.  The endocrine function of adipose tissues in health and cardiometabolic disease.

Authors:  Ludger Scheja; Joerg Heeren
Journal:  Nat Rev Endocrinol       Date:  2019-07-11       Impact factor: 43.330

6.  Pancreatitis is an FGF21-deficient state that is corrected by replacement therapy.

Authors:  Genaro Hernandez; Ting Luo; Tanveer A Javed; Li Wen; Michael A Kalwat; Kevin Vale; Farah Ammouri; Sohail Z Husain; Steven A Kliewer; David J Mangelsdorf
Journal:  Sci Transl Med       Date:  2020-01-08       Impact factor: 17.956

7.  FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition.

Authors:  Shannon M Reilly; Mohammad Abu-Odeh; Magdalene Ameka; Julia H DeLuca; Meghan C Naber; Benyamin Dadpey; Nima Ebadat; Andrew V Gomez; Xiaoling Peng; BreAnne Poirier; Elyse Walk; Matthew J Potthoff; Alan R Saltiel
Journal:  J Clin Invest       Date:  2021-05-17       Impact factor: 14.808

Review 8.  Metabolic Messengers: FGF21.

Authors:  Kyle H Flippo; Matthew J Potthoff
Journal:  Nat Metab       Date:  2021-03-18

9.  Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis.

Authors:  Ludger Scheja; Joerg Heeren
Journal:  Handb Exp Pharmacol       Date:  2022

Review 10.  Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies.

Authors:  Shuang Hua; Qianying Liu; Jufei Li; Mengqi Fan; Kaixuan Yan; Dewei Ye
Journal:  Rev Endocr Metab Disord       Date:  2021-06-13       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.